255 related articles for article (PubMed ID: 35728020)
21. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
Mahoney KM; Jacobus S; Bhatt RS; Song J; Carvo I; Cheng SC; Simpson M; Fay AP; Puzanov I; Michaelson MD; Atkins MB; McDermott DF; Signoretti S; Choueiri TK
Clin Genitourin Cancer; 2016 Aug; 14(4):304-313.e6. PubMed ID: 27036973
[TBL] [Abstract][Full Text] [Related]
23. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma.
Aeppli S; Eboulet EI; Eisen T; Escudier B; Fischer S; Larkin J; Gruenwald V; McDermott D; Oldenburg J; Omlin A; Porta C; Rini B; Schmidinger M; Sternberg C; Rothermundt C
ESMO Open; 2020 Jul; 5(Suppl 3):. PubMed ID: 32669298
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Sacré A; Barthélémy P; Korenbaum C; Burgy M; Wolter P; Dumez H; Lerut E; Loyson T; Joniau S; Oyen R; Debruyne PR; Schöffski P; Beuselinck B
Acta Oncol; 2016; 55(3):329-40. PubMed ID: 26494607
[TBL] [Abstract][Full Text] [Related]
25. Combination of immune checkpoint inhibitors and tyrosine kinase inhibitors for the treatment of renal cell carcinoma.
Stühler V; Rausch S; Maas JM; Stenzl A; Bedke J
Expert Opin Biol Ther; 2021 Sep; 21(9):1215-1226. PubMed ID: 33576709
[TBL] [Abstract][Full Text] [Related]
26. Expert Recommendations for First-Line Management of Metastatic Renal Cell Carcinoma in Special Subpopulations.
Puente J; García Del Muro X; Pinto Á; Láinez N; Esteban E; Arranz JÁ; Gallardo E; Méndez MJ; Maroto P; Grande E; Suárez C
Target Oncol; 2016 Apr; 11(2):129-41. PubMed ID: 26706236
[TBL] [Abstract][Full Text] [Related]
27. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K; Navani V; Ernst MS; Wells JC; Meza L; Pal SK; Lee JL; Li H; Agarwal N; Alva AS; Hansen AR; Basappa NS; Szabados B; Powles T; Tran B; Hocking CM; Beuselinck B; Yuasa T; Choueiri TK; Heng DYC
J Urol; 2023 Apr; 209(4):701-709. PubMed ID: 36573926
[TBL] [Abstract][Full Text] [Related]
28. Targeted Therapy for Metastatic Renal Cell Carcinoma.
Afriansyah A; Hamid AR; Mochtar CA; Umbas R
Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
[TBL] [Abstract][Full Text] [Related]
29. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma.
Varkaris A; Xu W; Davis RB; Healy B; McDermott DF
Clin Genitourin Cancer; 2020 Jun; 18(3):179-184.e3. PubMed ID: 32144046
[TBL] [Abstract][Full Text] [Related]
30. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
31. Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.
Soares A; Monteiro FSM; da Trindade KM; Silva AGE; Cardoso APG; Sasse AD; Fay AP; Carneiro APCD; Alencar Junior AM; de Andrade Mota AC; Santucci B; da Motta Girardi D; Herchenhorn D; Araújo DV; Jardim DL; Bastos DA; Rosa DR; Schutz FA; Kater FR; da Silva Marinho F; Maluf FC; de Oliveira FNG; Vidigal F; Morbeck IAP; Rinck Júnior JA; Costa LAGA; Maia MCDF; Zereu M; Freitas MRP; Dias MSF; Tariki MS; Muniz P; Beato PMM; Lages PSM; Velho PI; de Carvalho RS; Mariano RC; de Araújo Cavallero SR; Oliveira TM; Souza VC; Smaletz O; de Cássio Zequi S
J Cancer Res Clin Oncol; 2024 Apr; 150(4):183. PubMed ID: 38594593
[TBL] [Abstract][Full Text] [Related]
32. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma.
Gill DM; Hahn AW; Hale P; Maughan BL
Curr Treat Options Oncol; 2018 Jan; 19(1):6. PubMed ID: 29368125
[TBL] [Abstract][Full Text] [Related]
33. Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data.
de Bruijn R; Wimalasingham A; Szabados B; Stewart GD; Welsh SJ; Kuusk T; Blank C; Haanen J; Klatte T; Staehler M; Powles T; Bex A
Eur Urol Oncol; 2020 Apr; 3(2):168-173. PubMed ID: 31956080
[TBL] [Abstract][Full Text] [Related]
34. Treatment Landscape of Renal Cell Carcinoma.
Chen YW; Wang L; Panian J; Dhanji S; Derweesh I; Rose B; Bagrodia A; McKay RR
Curr Treat Options Oncol; 2023 Dec; 24(12):1889-1916. PubMed ID: 38153686
[TBL] [Abstract][Full Text] [Related]
35. Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Kyriakopoulos CE; Chittoria N; Choueiri TK; Kroeger N; Lee JL; Srinivas S; Knox JJ; Bjarnason GA; Ernst SD; Wood LA; Vaishampayan UN; Agarwal N; Pal SK; Kanesvaran R; Rha SY; Yuasa T; Donskov F; North SA; Heng DY; Rini BI
Clin Genitourin Cancer; 2015 Apr; 13(2):e79-85. PubMed ID: 25450036
[TBL] [Abstract][Full Text] [Related]
36. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
[TBL] [Abstract][Full Text] [Related]
37. Bone metastases and age are associated with earlier dose reductions in metastatic clear-cell renal cell carcinoma patients treated with angiogenesis inhibitors.
Haaker L; De Meue E; Wildiers H; Verbiest A; Dumez H; Lerut E; Pans S; Albersen M; Beuselinck B
Acta Clin Belg; 2019 Dec; 74(6):414-423. PubMed ID: 30497350
[No Abstract] [Full Text] [Related]
38. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
39. Managing Metastatic Renal Cell Carcinoma after Progression on Immunotherapy.
Barragan-Carrillo R; Govindarajan A; Rock A; Sperandio RC; Pal SK
Hematol Oncol Clin North Am; 2023 Oct; 37(5):965-976. PubMed ID: 37353376
[TBL] [Abstract][Full Text] [Related]
40. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]